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ABSTRACT
Background: Toxoplasma gondii (T. gondii) infection has been identified as a risk factor for schizophrenia. Objectives: Herein, we sought to evaluate the 
association between T. gondii infection and clinical symptoms and quality of life in patients with schizophrenia. Methods: We conducted a cross-sectional 
study with 48 patients with chronic schizophrenia and 40 controls. Peripheral blood was drawn, and IgM and IgG anti-T. gondii antibodies were evaluated 
by Enzyme-Linked Immunosorbent Assay (ELISA). Depressive, positive and negative symptoms were assessed, respectively, by the Calgary Depression Scale 
(CDS) and the Positive and Negative Syndrome Scale (PANSS). Cognitive performance was assessed in patients by the Brazilian version of the Schizophrenia 
Cognition Rating Scale (SCoRS-BR). Quality of life was assessed by the Brazilian version of the Quality of Life in Schizophrenia scale (QLS-BR). Results: The 
prevalence and titers of T. gondii IgM and IgG antibodies did not differ between patients and controls. The positive serology for T. gondii IgG antibodies was 
not associated with illness symptoms, cognitive performance, depressive symptoms or quality of life. Discussion: Our findings suggest that toxoplasmosis 
infection is not associated with severity of symptoms, quality of life, cognitive or depressive symptoms in schizophrenia patients.
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Introduction
Schizophrenia is a pervasive psychiatry disease whose etiopathogenesis 
results from complex gene-environmental interactions. Accumulating 
evidence suggests that infection is an important environmental factor 
implicated in schizophrenia pathogenesis1. Epidemiological and 
meta-analytic studies have shown an association between infections 
and increased risk of schizophrenia2. 
Toxoplasma gondii is a protozoan with a worldwide distribution3. 
It has been estimated that up to one third of the world population has 
been exposed to the parasite4. The exposure rate and the prevalence of 
T. gondii infection varies according to geographic region, population 
habits as well as socioeconomic conditions5. For instance, in Brazil the 
rate of T. gondii infection in humans is high: up to 50% of elementary 
school children and 50-80% of women of child-bearing age have 
antibodies to T. gondii6.
In healthy adults, infection with T. gondii generally results in a 
latent infection that persists for life. This chronic infection was largely 
regarded as asymptomatic, but this assumption has changed lately. 
Latent toxoplasmosis has been linked to changes in cognitive function 
in both children7 and elderly individuals8. T. gondii infection has 
also been regarded as a risk factor for schizophrenia. A recent meta-
analysis showed that T. gondii infection is associated with several 
psychiatric disorders including schizophrenia, bipolar disorder (BD) 
and obsessive-compulsive disorder9. Noteworthy, the reactivation of 
latent T. gondii infection may occur in patients with schizophrenia9. 
Moreover, T. gondii infection was associated with an increased risk 
for mortality in patients with schizophrenia10. 
Although the association between T. gondii infection and 
schizophrenia has already been investigated, the results are still 
controversial and only few studies have focused on whether the 
infection is associated with clinical outcomes. Therefore, this study 
was carried out to investigate differences in T. gondii seroprevalence 
in patients with schizophrenia and controls, as well as to evaluate 
whether seroprevalence and anti-T. gondii antibody titers are 
associated with clinical parameters.
Methods
Subjects
This is a cross-sectional study in which 48 patients with chronic 
schizophrenia and 40 controls were evaluated. Schizophrenia 
diagnosis was confirmed by the structured psychiatric interview 
MINI-Plus11 using the DSM-IV-TR criteria12.
Inclusion criteria for patients were: (a) age between 18-60 years; 
(b) diagnosis of schizophrenia; c) patients who were clinically stable as 
assessed by scores on the PANSS (see below). Controls were recruited 
from the local community using the following inclusion criteria (a) 
age between 18-60 years; (b) no current or past history of psychiatric 
disorder; (c) no family history of major psychiatry disorder. Exclusion 
criteria for both groups were: (a) history of epilepsy, dementia, brain 
trauma, tumor or other primary neurological diseases; (b) current 
dependence/use of drugs (alcohol, cannabis, cocaine, opioid); (c) 
current or recent (past four weeks) infections; (d) autoimmune or 
severe clinical diseases; (e) current or recent (past four weeks) use of 
corticosteroid or anti-inflammatory drugs. The study conformed to 
the declaration of Helsinki, with its protocol approved by the local 
Ethics Research Committee. Both patients and controls provided 
written informed consent.
Clinical, cognitive and quality of life assessments
Positive and negative symptoms were assessed by the Positive and 
Negative Syndrome Scale, PANSS13. Clinical stability was defined as 
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a PANSS positive score of 19 or less, and less than 4 in any individual 
item of the positive scale for at least four weeks. The clinical stability 
criterion was based on positive symptoms due to their high impact 
on cognitive functioning assessment. The validity and applicability 
of SCoRS has been demonstrated in patients with clinical stable 
schizophrenia, but not in patients with a recent exacerbation of the 
illness and/or with significant positive symptomatology14. The Calgary 
Depression Scale (CDS) was used to assess depressive symptoms15.
Cognitive performance was assessed by the Brazilian version of 
the Schizophrenia Cognition Rating Scale (SCoRS-BR)16. This is an 
interview-based scale that includes information provided by both the 
patient and an informant. It generates three different ratings: from the 
patient, from the informant and from the interviewer. The interview is 
composed of 18 items covering several cognitive domains, including 
memory, attention, reasoning and problem solving, working memory, 
motor skills and language. The total score is the sum of scores on the 
18 SCoRS items with a higher the score indicating greater degree of 
cognitive impairment. A global rating is also generated17.
Quality of life was assessed by the Quality of Life in Schizophrenia 
Scale (QLS) validated for use in Brazil (QLS-BR)18. This scale has a 
total of 21 items distributed among three factors: i) instrumental 
domain, ii) intrapsychic foundations and iii) interpersonal relations 
domain. Items include information on patient functioning during the 
three weeks preceding the interview. The sum of the values  obtained 
in the 21 items of the scale is used to assess the overall quality of life. 
Higher scores denote better quality of life.
Serological evaluation
Peripheral blood was drawn from each subject by venipuncture 
into a vacuum tube without anticoagulant. Blood was immediately 
centrifuged at 3,000 rpm for 10 minutes, serum was collected and kept 
frozen at -80°C until assayed. IgM and IgG anti-T. gondii antibodies 
were determined by Enzyme-Linked Immunosorbent Assay (ELISA), 
using kits SERION - ELISA classic test by VIRION (Würzburg, 
Germany), following the manufacturer’s guidelines. The test 
sensitivity were 10 IU/mL and 5 IU/mL to IgM and IgG, respectively.
Statistical analysis
All variables were tested for Gaussian distribution by the Kolmogorov-
Smirnov normality test. Association between dichotomous variables 
was assessed with the Fisher’s exact test. Two groups were compared 
by Mann-Whitney or Student’s t tests when non-normally or 
normally distributed, respectively. Spearman’s correlation analyses 
were performed for correlation analyses. All statistical tests were 
two-tailed and were performed using a significance level of α = 0.05. 
Statistical analyses were performed using SPSS software version 
22.0 (SPSS Inc., Chicago, IL, USA), as well as GraphPad Prism 5.0 
(GraphPad Software, Inc., La Jolla, California, EUA).
Results 
Demographic and clinical data
Demographic and clinical data are shown in Table 1. Patients and 
controls did not differ regarding age and gender. Patients with 
schizophrenia had less years of formal education than controls. The 
mean (± SD) length of illness was 15.20 (± 10.50) years. The mean 
(± SD) scores in the positive and negative subscales of the PANSS 
were, respectively, 10.28 (± 2.78) and 19.67 (± 7.73), indicating a 
chronic condition with predominance of negative symptoms. 
Table 1. Demographic, clinical and serological features of controls and patients
  Controls (N = 40) Patients SZ (N = 48) p values
Male gender [frequency in % (N)] 42.50 (17) 56.25 (27) 0.284a
Age in years (mean ±SD) 40.62 ± 10.29 40.21 ± 9.59 0.845b 
Educational levels in years (mean ±SD) 12.25 ± 4.77  8.04 ± 4.25 < 0.001c
Age of onset in years (mean ±SD) _ 24.58 ± 9.91 _
Length of illness in years (mean ±SD) _ 15.20 ± 10.50 _
Medication in use [frequency in % (N)]
    Potent typical antipsychotics _ 60.86 (28) _
    Sedatives typical antipsychotics _ 39.13 (18) _
    Atypical antipsychotics _ 34.78 (16) _
    Clozapine _ 4.34 (2) _
    Mood stabilizers _ 8.69 (4) _
    Antidepressants _ 6.52 (3) _
Chlorpromazine equivalent (mean ±SD) _ 351.74 ± 232.29 _
Preview electroconvulsive therapy [frequency in % (N)] _ 8.33 (4) _
PANSS (mean ±SD)
     Positive _ 10.28 ± 2.78 _
     Negative _ 19.67 ± 7.73 _
     General _ 26.22 ± 7.27 _
     Total _ 56.55 ± 12.07 _
CDS (mean ±SD) _ 1.95 ± 2.54 _
SCoRS-BR (mean ±SD)
     SCoRS-BR patient _ 37.48 ± 11.12 _
     SCoRS-BR informant _ 36.59 ± 10.40 _
     SCoRS-BR interviewer _ 40.49 ± 11.38 _
     SCoRS-BR global _ 5.64 ± 1.58 _
QLS-BR total /126 (mean ±SD) _ 54.41 ± 24.76 _
Positive IgM antiboties anti-T. gondii (%) (N) 7.50 (3) 4.17 (2) 0.656a
Positive IgG antibodies anti-T. gondii (%) (N) 56.41 (22)d 56.25 (27) 1.000a
IgM IU/mL (mean ± SD) 130.67 ± 114.82 121.31 ± 97.99 0.630c
IgG IU/mL (mean ± SD) 115.59 ± 166.53 127.58 ± 218.12 0.785c
a Fisher’s exact test; b Student’s t test; c Mann-Whitney test; d One individual presented indeterminate results for IgG.
CDS: Calgary Depression Scale; PANSS: Positive and Negative Syndrome Scale; QLS-BR: Quality of Life in Schizophrenia scale validated for use in Brazil; SCoRS-BR: Brazilian version of the Schizophrenia 
Cognition Rating Scale; SD: standard deviation.
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Table 2. Demographic, clinical, cognitive performance and quality of life in patients with schizophrenia, according to serology for IgG anti-T.gondii
  Seronegative (N = 21) Seropositive (N = 27) p value
Male gender [frequency in % (N)] 66.67 (14) 48.15 (13) 0.249a
Age in years (mean ±SD) 39.71 ± 10.10 40.59 ± 9.35 0.757b
Educational level in years (mean ±SD) 8.10 ± 4.81 8.00 ± 3.86 0.940b
Age of onset in years (mean ±SD) 23.25 ± 9.81 25.61 ± 10.04 0.428b
Length of illness in years (mean ±SD) 15.94 ± 11.19 14.69 ± 10.37 0.715b
Chlorpromazine equivalent (mean ±SD) 375.78 ± 233.31 333.71 ± 234.49 0.637c
PANSS (mean ±SD)
     Positive 10.67 ± 2.82 9.96 ± 2.76 0.306c
     Negative 21.24 ± 7.97 18.36 ± 7.41 0.212b
     General 28.05 ± 6.49 24.76 ± 7.66 0.133b
     Total 58.50 ± 11.75 54.77 ± 12.35 0.324b
CDS (mean ±SD) 1.81 ± 2.31 2.04 ± 2.72 0.777c
SCoRS-BR (mean ±SD)
     SCoRS-BR patient 35.70 ± 9.19 38.85 ± 12.40 0.431c
     SCoRS-BR informant 32.65 ± 6.57 39.64 ± 11.86 0.072c
     SCoRS-BR interviewer 36.71 ± 7.65 43.41 ± 13.01 0.124c
     SCoRS-BR global 5.27 ± 1.07 5.95 ± 1.88   0.591b
QLS-BR total/126 (mean ±SD) 60.65 ± 25.76 49.10 ± 23.20 0.160b
a Fisher’s exact test; b Student’s t test; c Mann-Whitney test.
CDS: Calgary Depression Scale; PANSS: Positive and Negative Syndrome Scale; QLS-BR: Quality of Life in Schizophrenia scale validated for use in Brazil; SCoRS-BR: Brazilian version of the Schizophrenia 
Cognition Rating Scale; SD: standard deviation.
T. gondii seroprevalence and association with clinical 
parameters
Patients with schizophrenia and controls presented similar 
seroprevalence and titers for both IgG and IgM anti-T. gondii 
antibodies (Table 1). 
Patients with schizophrenia were then categorized into two 
groups: anti-T gondii IgG positive (Toxoplasma-seropositive, N = 27) 
and anti-T gondii IgG negative (Toxoplasma-seronegative, N = 21). 
We did not find any difference between Toxoplasma-seronegative and 
Toxoplasma-seropositive patients regarding age, gender, educational 
level, age of onset, length of illness, chlorpromazine equivalent 
level and PANSS subsets (Table 2). Toxoplasma-seropositive and 
Toxoplasma-seronegative patients presented similar scores in the 
scales that evaluated depressive symptoms, cognitive performance 
and quality of life (Table 2). 
We did not find any significant correlation between anti-T. 
gondii IgM and IgG levels and age, age at onset, duration of illness, 
chlorpromazine equivalent level, positive PANSS, negative PANSS, 
total PANSS, patient SCoRS, informant SCoRS, interviewer SCoRS, 
global SCoRS, CDS or QLS scores. No difference was found when 
comparing male and female participants.
Discussion 
The current study was conducted in order to compare the prevalence 
of T. gondii infection between patients with schizophrenia and 
controls, as well as to evaluate the potential association between 
T. gondii infection and clinical symptoms in Brazilian patients 
with schizophrenia. We found similar rates of positive serological 
reaction to T. gondii in controls and patients with schizophrenia. 
In addition, we did not find any association between T. gondii 
seroprevalence and demographic data, positive, negative and 
depressive symptoms, cognitive performance and quality of life in 
patients with schizophrenia. 
Previous studies found higher rates of T. gondii infection in 
patients with schizophrenia in comparison with controls19-23. In 
contrast, some authors have questioned this association24,25. A recent 
meta-analysis reported a significant association between T. gondii 
infection as estimated by IgG antibodies and schizophrenia (odds 
ratio 1.81, P < 0.0001). A very high heterogeneity was observed 
among studies, and the amplitude of the odds ratio was influenced 
by region and general seroprevalence9. Accordingly, the possibility 
of finding association between toxoplasmosis and schizophrenia 
is lower in regions with high seroprevalence rates when compared 
with regions with low rates. Brazil has a high prevalence of T. gondii 
infection which could be an explanation for the current findings. 
Moreover, our sample was composed by chronic patients under 
high dose of antipsychotics that may affect anti-T. gondii IgG titers26.
T. gondii infection has been associated with symptom severity 
in schizophrenia23,27,28. In addition, latent toxoplasmosis may have 
a negative impact on the disease  course and treatment response 
in patients with schizophrenia29. Corroborating these clinical 
data, patients with schizophrenia T. gondii-seropositive presented 
more significant morphological changes in the caudate, cingulate, 
thalamus and occipital cortex in comparison with seronegative 
patients30. In the current study, we did not find significant differences 
between seropositive and seronegative patients regarding the clinical 
symptoms of schizophrenia as assessed by PANSS. The fact that 
the enrolled patients were clinically stable comprising a relatively 
homogenous sample may partially explain this result. 
Data on whether T. gondii infection is associated with cognitive 
aspects in schizophrenia are still controversial. For instance, one 
study showed that people diagnosed with schizophrenia who were 
exposed in utero to T. gondii presented impaired performance in two 
executive function tests: the Wisconsin Card Sorting Test (WCST) 
and the Trail Making Test (TMT) part B31. These patients also 
exhibited deficits on figural fluency, letter-number sequencing and 
backward digit span31. Conversely, other studies failed to show any 
association between latent toxoplasmosis and cognitive function in 
schizophrenia32,33. According to our results, T. gondii infection is not 
associated with self-reported cognitive performance as evaluated by 
the SCoRS. Discrepancies among studies can also be explained, at 
least in part, by strain related specific effects of T. gondii on human 
brain9. Indeed, regional differences in strain distribution have been 
reported, and T. gondii strain-specific effects in depression have 
already been demonstrated9. 
It is worth mentioning that the use of antipsychotic and/or mood 
stabilizers presenting in vitro anti-toxoplasmic activity was associated 
with a better clinical outcome in a population of BD patients. Patients 
with BD seropositive for T. gondii presented more lifetime depressive 
episodes when treated by drugs having no anti-toxoplasmic activity 
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(e.g. aripiprazole, carbamazepine, clozapine, lamotrigine, lithium, 
olanzapine, quetiapine) compared to patients who received drugs 
with anti-toxoplasmic activity (e.g. fluphenazine, haloperidol, 
levomepromazine, paliperidone, risperidone, thioridazine, 
valproate)34. It remains to be determined whether the treatment with 
drugs with anti-toxoplasmic activity is also associated with better 
clinical outcomes of the patients with schizophrenia.    
We are aware of the limitations of our study. First the sample size 
is small and consists of chronic patients using antipsychotics. It is 
uncertain whether our results can be applied to patients with prodromal 
or early schizophrenia. Cohort studies involving a larger sample of 
drug naïve patients are critical to confirm the specificity to clarify 
the pathogenic role of T. gondii in schizophrenia and its symptoms. 
Cognitive assessment of patients was based on self-reported measures. 
Although SCoRS is highly correlated to cognitive performance and 
functioning, a comprehensive neuropsychological evaluation in both 
patients and controls could add more specific information, including 
the domains potentially affected by toxoplasmosis. 
In conclusion, our data showed that T. gondii infection is not 
associated with schizophrenia. In addition, T. gondii seroprevalence 
and levels of IgG antibodies were not associated with demographic 
data, disease severity, depressive and cognitive symptoms and quality 
of life. Our results might be influenced by strain-specific brain 
effects and high prevalence of T. gondii infection in our sample. 
Further studies are needed in order to elucidate the role of T. gondii 
in schizophrenia pathophysiology. 
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